Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study

In patients with moderate‐to‐severe RA and an inadequate response to methotrexate (n=190), ACR20 response rates at week 12 were not statistically significantly different to placebo for any dose studied; differences for the higher doses however reached significance at week 24.

Source:

Arthritis & Rheumatology